Pogłód R
Department of Haematology, Institute of Haematology, Warzawa, Poland.
Mater Med Pol. 1990 Jan-Mar;22(1):36-42.
The purpose of the study was assessment of the effectiveness of treatment applied in nine proliferative diseases of the haemopoietic system (PDHS) in the years 1951-1980. The effectiveness was determined comparing the mean survival time in each of these diseases in three 10-year-time periods characterised by essential changes in their treatment. Moreover, other factors were studied which may influence the survival time in these diseases. A continuing increase in the survival time correlated with advances in therapy was observed in acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), Hodgkin's disease (HD) and multiple myeloma (MM). An indicator of the advances in the treatment of acute leukaemias was also an over fourfold rise in the likelihood of achieving complete remission in the decade 1971-1980 in relation to two preceding decades. On the other hand, no improvement of the effectiveness of treatment was noted in chronic myeloid leukaemia (CML), polycythaemia vera (PV), myelofibrosis (MF) and non-Hodgkin lymphomas (NHL). The length of the survival time was influenced also considerably by patient's age (survival lower in old age), sex (better results in women) and place of residence of the patient (worse results in patients living in rural areas).
该研究的目的是评估1951年至1980年间应用于九种造血系统增殖性疾病(PDHS)的治疗效果。通过比较这些疾病在三个以治疗方法发生根本变化为特征的10年期内各自的平均生存时间来确定治疗效果。此外,还研究了其他可能影响这些疾病生存时间的因素。在急性髓细胞白血病(AML)、急性淋巴细胞白血病(ALL)、霍奇金病(HD)和多发性骨髓瘤(MM)中观察到生存时间的持续增加与治疗进展相关。1971年至1980年这十年间,急性白血病治疗进展的一个指标是完全缓解可能性相对于前两个十年增加了四倍多。另一方面,在慢性髓细胞白血病(CML)、真性红细胞增多症(PV)、骨髓纤维化(MF)和非霍奇金淋巴瘤(NHL)中未观察到治疗效果的改善。生存时间的长短还在很大程度上受到患者年龄(老年患者生存时间较短)、性别(女性治疗效果较好)和患者居住地(农村地区患者治疗效果较差)的影响。